Skip to content
Peptigraph home

Tesamorelin and IGF-1 LR3 Together: What Is Known

Tesamorelin and IGF-1 LR3 taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH analogFDA approved (Egrifta)TesamorelinFDA-approved GHRH analog (Egrifta) for excess abdominal fat in HIV-associated lipodystrophy; visceral fat fell 15.2% versus a 5.0% rise with placebo in a randomized trial.[15]Growth hormoneIGF-1 analogNot FDA approved · research chemicalIGF-1 LR3IGF-1 LR3, a long-acting IGF-1 analog with no published human trial; in rats it was 2.5 to 3 times more potent than IGF-I at restoring growth.[16]Growth hormone
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 1 result, 2 Oct 2026).

We have no sourced data on taking these two together. Ask the prescriber who manages both.
Each component

Side by side

Showing 12 of 14 fields where the two differ. Category, PCAC vote, Jul 2026 are the same or both unknown.

FieldTesamorelinIGF-1 LR3
ClassGHRH analogIGF-1 analog
Also calledtesa, EgriftaLR3
FDA statusFDA approved (Egrifta)Not FDA approved · research chemical
WADAProhibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption.Prohibited by WADA (S2.3)IGF-1 and its analogues (LR3 is an IGF-1 analogue) are prohibited in S2.3, at all times.
Anti-doping detection
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
None reportedanti-doping literature, as of 2 Oct 2026
Half-life11 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR)563 min half-life in wound fluid (versus 872 min for IGF-I)wound chamber (rat) (rat) · The American journal of physiology 1999, PMID 10198302
Evidence strengthHuman RCT evidence, 4 of 4Strongest: eNeurologicalSci 2026, PMID 42382101Human observational evidence, 3 of 4Strongest: Growth hormone & IGF research 2010, PMID 20675162
Human studies we summarised11 human (11 randomized or controlled) of 12 summarised1 human (0 randomized or controlled) of 12 summarised
Typical study doses
Vial sizes sold2 mg, 5 mg, 10 mg, 20 mg0.1 mg, 1 mg
US searches per month165,000 · +188% searches22,200 · +230% searches
Named in FDA warning letters, 2026Yes (24 Aug 2026)Not in the letters we track
Related tools

Tesamorelin vs IGF-1 LR3

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison
ComparisonIGF-1 LR3 vs Tesamorelin

What people search

  • tesamorelin and igf 1 lr330/mo
  • tesamorelin igf 1 lr320/mo
  • igf 1 lr3 with tesamorelin20/mo
  • tesamorelin with igf 1 lr310/mo
  • igf 1 lr3 tesamorelin10/mo
  • igf 1 lr3 and tesamorelin10/mo

US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  4. 4Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  5. 5EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  6. 6The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
  7. 7Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
  8. 8The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
  9. 9Clearance of IGFs and insulin from wounds: effect of IGF-binding protein interactions.The American journal of physiology · 1999PMID 10198302Accessed 2 Oct 2026
  10. 10Detection of His-tagged Long-R³-IGF-I in a black market product.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2010PMID 20675162Accessed 2 Oct 2026
  11. 11IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.American journal of physiology. Endocrinology and metabolism · 2025PMID 39679943Accessed 2 Oct 2026
  12. 12Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.Journal of Alzheimer's disease : JAD · 2025PMID 39610283Accessed 2 Oct 2026
  13. 13Insulin-like growth factor-I and analogues increase growth in artificially-reared neonatal pigs.The British journal of nutrition · 2002PMID 12067429Accessed 2 Oct 2026
  14. 14PubMed search: ("Long R3"[tiab] OR (LR3[tiab] AND (IGF[tiab] OR "IGF-1"[tiab] OR "IGF-I"[tiab] OR "insulin-like growth factor"[tiab]))) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
  16. 16Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects.The Biochemical journal · 1993PMID 7683875Accessed 2 Oct 2026

Found an error? Report a correction.